If female reproductive cancers (breast and gynecological cancers combined) were to be eliminated, the overall female survival advantage would increase by approximately 0.77 years on average, with country-specific increases ranging up to nearly one year.
Wen Su
Using a novel mortality measure (Truncated Cross-sectional Average Length of Life), we show a pattern of elevated female cancer mortality in midlife that was consistent across birth cohorts.
Wen Su
Paper led by colleagues from Australian National University is out now in JAMANetworkOpen. We used novel mortality measure to quantify how female reproductive cancers affect female survival advantages over male across ages and cohorts among high-income countries. jamanetwork.com/journals/jam....
Wen Su
This cohort study quantifies differences in survival over time between males and females and examines how female reproductive cancers are associated with these differences.
